Argenica Therapeutics (ASX:AGN) has dosed 80% of patients in its Phase 2 trial for ARG-007, a promising stroke therapy, with no adverse safety concerns reported.
Variscan Mines triples the high-grade Mineral Resource Estimate at Novales-Udías to 3.4Mt @ 7.6% Zn, solidifying its position as a top-tier European zinc project.
China’s critical minerals export ban has opened a major opportunity for Australia to step up as a global supplier of essential materials like gallium, germanium, and antimony.
Trigg Minerals (ASX:TMG) is employing cutting-edge UAV geophysical technologies to unlock the mineral potential of the Wild Cattle Creek deposit, targeting critical minerals such as tungsten and antimony.
Warriedar Resources (ASX:WA8) uncovers high-grade antimony mineralisation at Azure Coast, enhancing the critical minerals potential of its Golden Range Project in Western Australia.
Orthocell’s Remplir™ is set to transform nerve repair surgery by overcoming traditional limitations like inflammation and scarring, offering surgeons a reliable tool for consistent outcomes.
Warriedar Resources’ Ricciardo deposit demonstrates promising antimony potential, with 83% recovery and marketable concentrate grades, positioning it as a key player in Australia’s critical minerals sector.
Green Technology Metals (ASX: GT1) advances its Root Lithium Project with high-grade results of 17.3m at 1.80% Li₂O, bolstering underground mining potential.
Lunnon Metals (ASX: LM8) is uncovering high-grade, near-surface gold intercepts at Lady Herial, strengthening its case for a new gold discovery within Australia’s iconic Kambalda region.
Island Pharmaceuticals (ASX:ILA) has achieved a major milestone with its lead drug ISLA-101, showing safety and anti-dengue activity in Phase 2a trials, paving the way for therapeutic testing.